Tuesday, October 02, 2018 8:35:57 AM
https://ciiien2018.org/
We can now see what the PM initiative brings. He speaks w/authority about those aspects of AD treatment/cause which we have heard nothing until now. Could it be that this level of understanding is what caused BP to drop the Amyloid Thesis late 2017, like they were part of a drill team. The contest of proof by trial vs proof by knowledge and PM is just about over, except for BAN-BIIB still underway b/c they did not get the memo. Will that AHAHA moment occur at CTAD?
As the learning process grinds on through the next level a lot of people and institutions have some splainen to do. As Dr.Peter Senge says there are 3 levels of knowledge.
#1. The things we know.
#2. The things we do not know(but), we KNOW we don't know them. (see HH).
#3 The things we do not know, we do not know. (this is the stuff that kills you.).
Learning occurs at the interface defined by (#2) above, which is what the PM initiative is all about, it is the PM process which enables learning. HH is pushing at the( #2. interface) . There is an old semiconductor depletion region analogy(sorry investor) for this interface which might work here. It says that the charge at the (#2) +/- interface must be balanced,(watch out for analogy) it is called the depletion region in physics. so where +=knowledge then +++ will have a large learning interface GAP (strong charge or attraction for new knowledge)so, more knowledge will be generated quickly, conversely when the depletion region is small (Weak-constrained by lack of knowledge) then the learning process will stop or move only slowly by surface leakage until more powerful knowledge is brought to the interface. (w/o a PM process some small leakage will occur at this interface but PM must be applied to move the boundary of #2 into #1). HH makes the point that many things must be learned/evaluated before any balloons go up, BUT IMO, patients will benefit at each learning stage along the way until the science is settled. ALL IMO.
We can now see what the PM initiative brings. He speaks w/authority about those aspects of AD treatment/cause which we have heard nothing until now. Could it be that this level of understanding is what caused BP to drop the Amyloid Thesis late 2017, like they were part of a drill team. The contest of proof by trial vs proof by knowledge and PM is just about over, except for BAN-BIIB still underway b/c they did not get the memo. Will that AHAHA moment occur at CTAD?
As the learning process grinds on through the next level a lot of people and institutions have some splainen to do. As Dr.Peter Senge says there are 3 levels of knowledge.
#1. The things we know.
#2. The things we do not know(but), we KNOW we don't know them. (see HH).
#3 The things we do not know, we do not know. (this is the stuff that kills you.).
Learning occurs at the interface defined by (#2) above, which is what the PM initiative is all about, it is the PM process which enables learning. HH is pushing at the( #2. interface) . There is an old semiconductor depletion region analogy(sorry investor) for this interface which might work here. It says that the charge at the (#2) +/- interface must be balanced,(watch out for analogy) it is called the depletion region in physics. so where +=knowledge then +++ will have a large learning interface GAP (strong charge or attraction for new knowledge)so, more knowledge will be generated quickly, conversely when the depletion region is small (Weak-constrained by lack of knowledge) then the learning process will stop or move only slowly by surface leakage until more powerful knowledge is brought to the interface. (w/o a PM process some small leakage will occur at this interface but PM must be applied to move the boundary of #2 into #1). HH makes the point that many things must be learned/evaluated before any balloons go up, BUT IMO, patients will benefit at each learning stage along the way until the science is settled. ALL IMO.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
